Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that
are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease …

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …

The efficacy of vaccine adjuvants such as Toll-like receptor agonists (TLRa) can be
improved through formulation and delivery approaches. Here, we attached small molecule …

Infectious diseases are a major cause for morbidity and mortality in the older population.
Demographic changes will lead to increasing numbers of older persons over the next …

The need for new adjuvants is absolutely cardinal to the development of new vaccines and
to further optimizing current immunization approaches. However, only a few classes of …

Although current anticancer immunotherapies using immune checkpoint inhibitors (ICIs)
have been reported with a high clinical success rate, numerous patients still bear …

Vaccine adjuvants interact with the immune system, to increase the potency of vaccine
antigens. Many of the adjuvants currently available were developed with little understanding …

Highlights•New adjuvants are typically a combination of delivery system and an immune
potentiator.•A deeper understanding of innate immunity has helped the discovery of new …

The separation of molecular compounds based on their capacity to access the intra-particle
pore volume of chromatographic media, which is dictated by the relative size in solution of …

Self-adjuvanting protein vaccines have been proved to be highly immunogenic with efficient
codelivery of adjuvant and antigen. Current protein vaccines with built-in adjuvants are all …